Hampered by historical paradigms – echinocandins and the treatment of Candida endocarditis

Authors

  • B. J. Gardiner,

    Corresponding author
    1. Monash Infectious Diseases, Monash Medical Centre, Clayton, Vic., Australia
    • Correspondence: Dr B. Gardiner, Monash Infectious Diseases, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia.

      Tel.: +613 9594 4564. Fax: +61 3 9594 4533.

      E-mail: bradgardiner@gmail.com

    Search for more papers by this author
  • M. A. Slavin,

    1. Peter MacCallum Cancer Centre and Faculty of Medicine, University of Melbourne, Melbourne, Vic., Australia
    Search for more papers by this author
  • T. M. Korman,

    1. Monash Infectious Diseases, Monash Medical Centre, Clayton, Vic., Australia
    2. Department of Medicine, Monash University, Clayton, Vic., Australia
    Search for more papers by this author
  • R. L. Stuart

    1. Monash Infectious Diseases, Monash Medical Centre, Clayton, Vic., Australia
    2. Department of Medicine, Monash University, Clayton, Vic., Australia
    Search for more papers by this author

Summary

Infective endocarditis due to Candida sp. has a high mortality rate. Traditionally, management involves early surgery and prolonged amphotericin ± flucytosine. We report a case of Candida parapsilosis bileaflet mitral valve endocarditis cured with anidulafungin and fluconazole, and review the role of echinocandins in the management of Candida endocarditis.

Ancillary